Lepu Biopharma 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Ziye Sui

최고 경영자

CN¥8.8m

총 보상

CEO 급여 비율	22.1%
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	3.6yrs
이사회 평균 재임 기간	3.9yrs

최근 관리 업데이트

Recent updates

Lepu Biopharma (HKG:2157) Is Making Moderate Use Of Debt

Aug 23

The Price Is Right For Lepu Biopharma Co., Ltd. (HKG:2157) Even After Diving 27%

Jul 18

Lepu Biopharma Co., Ltd. (HKG:2157) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing

Jun 03

Revenues Not Telling The Story For Lepu Biopharma Co., Ltd. (HKG:2157) After Shares Rise 26%

Apr 15

CEO 보상 분석

Ziye Sui 의 보수는 Lepu Biopharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-CN¥73m
Mar 31 2024	n/a	n/a	-CN¥47m
Dec 31 2023	CN¥9m	CN¥2m	-CN¥22m
Sep 30 2023	n/a	n/a	-CN¥254m
Jun 30 2023	n/a	n/a	-CN¥487m
Mar 31 2023	n/a	n/a	-CN¥588m
Dec 31 2022	CN¥9m	CN¥2m	-CN¥689m
Sep 30 2022	n/a	n/a	-CN¥766m
Jun 30 2022	n/a	n/a	-CN¥843m
Mar 31 2022	n/a	n/a	-CN¥927m
Dec 31 2021	CN¥12m	CN¥2m	-CN¥1b
Dec 31 2020	CN¥2m	CN¥1m	-CN¥582m

보상 대 시장: Ziye 의 총 보상 ($USD 1.21M )은 Hong Kong 시장( $USD 479.01K ).

보상과 수익: Ziye 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Ziye Sui (43 yo)

less than a year

테뉴어

CN¥8,789,000

보상

Dr. Ziye Sui, M.D. Ph.D. had been Non-Executive Director of Star Combo Pharma Ltd since June 21, 2018 until August 24, 2022. She is the Vice President of Lepu Medical Technology (Beijing) Co. Limited. She...

리더십 팀

이름	위치	테뉴어	보상	소유권
Zhongjie Pu	Executive Chairman	6.8yrs	데이터 없음	25.33% HK$ 1.2b
Ziye Sui	CEO & Director	less than a year	CN¥8.79m	데이터 없음
Yunyi Li	CFO & Board Secretary	3.9yrs	데이터 없음	데이터 없음
Minmin Qin	Chief Technology Officer	3.9yrs	데이터 없음	데이터 없음
Lixuan Zhao	Supervisor & Investor Relations Director	1.7yrs	데이터 없음	데이터 없음
Siu Kuen Lai	Joint Company Secretary	3.6yrs	데이터 없음	데이터 없음

3.6yrs

평균 재임 기간

46yo

평균 연령

경험이 풍부한 관리: 2157 의 관리팀은 경험 ( 3.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Zhongjie Pu	Executive Chairman	6.8yrs	데이터 없음	25.33% HK$ 1.2b
Ziye Sui	CEO & Director	4.6yrs	CN¥8.79m	데이터 없음
Lixuan Zhao	Supervisor & Investor Relations Director	less than a year	데이터 없음	데이터 없음
Fengmao Hua	Independent Non-Executive Director	2.9yrs	CN¥250.00k	데이터 없음
Yang Xu	Supervisor	3.9yrs	데이터 없음	데이터 없음
Haifeng Yang	Independent Non-Executive Director	3.9yrs	CN¥250.00k	데이터 없음
Hongbing Yang	Non-Executive Director	4.6yrs	데이터 없음	데이터 없음
Jue Pu	Non-Executive Director	4.6yrs	데이터 없음	5.26% HK$ 258.3m
Demin Zhou	Independent Non-Executive Director	3.9yrs	CN¥250.00k	데이터 없음
Ming Yang	Supervisor	3.9yrs	데이터 없음	데이터 없음

3.9yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 이사회: 2157 의 이사회는 경험(평균 재직 기간 3.9 년)으로 간주됩니다.

Lepu Biopharma 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Lepu Biopharma Co., Ltd., Annual General Meeting, Jun 19, 2024

Less than half of directors are independent

Less than half of directors are independent

Lepu Biopharma Co., Ltd., Annual General Meeting, Jun 21, 2022

Less than half of directors are independent

Recent updates

Lepu Biopharma Co., Ltd. Receives the Acceptance Notice Issued by China National Medical Products Administration

First half 2024 earnings released: CN¥0.12 loss per share (vs CN¥0.086 loss in 1H 2023)

New major risk - Financial position

First half 2024 earnings released: CN¥0.12 loss per share (vs CN¥0.086 loss in 1H 2023)

Lepu Biopharma (HKG:2157) Is Making Moderate Use Of Debt

Lepu Biopharma Co., Ltd. to Report First Half, 2024 Results on Aug 21, 2024

Lepu Biopharma Co., Ltd. Announces Breakthrough Therapy Designation Granted by the FDA to MRG003 for the Treatment of R/M NPC

The Price Is Right For Lepu Biopharma Co., Ltd. (HKG:2157) Even After Diving 27%

Lepu Biopharma Co., Ltd. (HKG:2157) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing

New minor risk - Shareholder dilution

Lepu Biopharma Co., Ltd. Announces Three Clinical Trial Results Presented At 2024 Asco Annual Meeting

Lepu Biopharma Co., Ltd. has filed a Follow-on Equity Offering in the amount of HKD 234.3586 million.

Full year 2023 earnings released: CN¥0.013 loss per share (vs CN¥0.42 loss in FY 2022)

Lepu Biopharma Co., Ltd., Annual General Meeting, Jun 19, 2024

Revenues Not Telling The Story For Lepu Biopharma Co., Ltd. (HKG:2157) After Shares Rise 26%

Lepu Biopharma Co., Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

Lepu Biopharma Co., Ltd. Receives Fast Track Designation by the Food and Drug Administration of the United States for the Treatment of Pancreatic Cancer

New minor risk - Share price stability

Lepu Biopharma Co., Ltd. Announces Completion of Patient Enrollment of Pivotal Phase IIb Clinical Trial for MRG003 for the Treatment of R/M NPC

Lepu Biopharma Co., Ltd. Announces Orphan-Drug Designation Granted by the FDA to MRG004A for the Treatment of Pancreatic Cancer

Lepu Biopharma Co., Ltd. to Report First Half, 2023 Results on Aug 25, 2023

Lepu Biopharma Co., Ltd. Provides Update on the Data from Phase Ia Clinical Study of CMG901

Less than half of directors are independent

Lepu Biopharma Co., Ltd. Announces Conditional Marketing Approval Obtained in China Forpuyouheng (Pucotenlimab Injection) for Thetreatment of Inoperable or Metastatic Melanoma

Lepu Biopharma Co., Ltd. to Report First Half, 2022 Results on Aug 25, 2022

Anti-PD-1 Monoclonal Antibody Puyouheng Co-developed by LEPU BIOPHARMA and HANX BIOPHARMACEUTICALS Approved for Marketing in China by NMPA

Lepu Biopharma Co., Ltd. Receive Conditional Marketing Approval Obtained in China for Puyouheng (Pucotenlimab Injection) for the Treatment Inhigh Levels of Microsatellite Instability/Deficient Mismatch Repair (MSI-H/dMMR)

Less than half of directors are independent

Lepu Biopharma Co., Ltd., Annual General Meeting, Jun 21, 2022

Lepu Biopharma Co., Ltd. has completed an IPO in the amount of HKD 904.62588 million.

Less than half of directors are independent

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령